Author: admin

TRYGVE Innovative Business Model, Expanding Its Footprint in the High-Value Asset Leasing Market

NY – December 5, 2024 – Renowned asset management technology company TRYGVE LLC has launched a new business model, further solidifying its leadership in the high-value asset leasing market. This transformative shift marks a significant milestone for the company, demonstrating its commitment to providing innovative solutions for its clients.

TRYGVE has long been a leader in the B2C consumer leasing market. However, recognizing the need to adapt to a rapidly evolving industry landscape, the company transitioned to a B2B-focused business model. This shift centers on leasing high-value assets such as aircraft, yachts, luxury cars, and other premium assets.

“We are thrilled to introduce our new business model, which will enable us to expand our reach in the high-value asset leasing market,” said Michael Robert, CEO of TRYGVE. “Our team has worked tirelessly to develop innovative solutions tailored to the specific needs of our clients. This transformation benefits not only our company but also our partners and customers.”

Innovative Supply Chain Model Driving Global Collaboration and Technology Integration

Since 2019, TRYGVE has partnered with its long-term ally CEDG to establish a groundbreaking supply chain model. CEDG oversees the development and management of asset suppliers, ensuring operational stability and compliance. In 2020, the model evolved to include both individual and corporate suppliers. TRYGVE directly leases assets from suppliers and subleases them to global leasing companies, reducing risks for suppliers and stabilizing their returns.

In 2021, TRYGVE, in collaboration with CEDG and strategic partner WYOBIZ, integrated resources from a luxury online retail platform. Suppliers can purchase luxury items directly through the platform and lease them to TRYGVE to generate stable rental income. To date, over 200 individual suppliers and 12 corporate suppliers have participated in this program, promoting the global circulation of high-value assets.

TRYGVE leverages advanced asset tracking technology and comprehensive insurance coverage to ensure the safety and reliability of leasing transactions while significantly improving asset utilization.

CEDG’s Managing Director commented, “TRYGVE’s model maximizes supplier returns while simplifying asset management complexities. We’re also pleased that general consumers can now access this market with lower entry barriers.”

WYOBIZ LLC’s representative added, “This collaboration has not only enhanced sales performance on our platform but also introduced more consumers to the potential of the leasing market.”

Looking Ahead

TRYGVE plans to further expand its operations in European and Asian markets, offering more tailored leasing solutions for individuals and SMEs. The company remains committed to strengthening collaborations with global partners to build a more inclusive and innovative asset management ecosystem.

Media Contact
Company Name: TRYGVE LLC
Contact Person: Michael Robert
Email: Send Email
Country: United States
Website: trygve-llc.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: TRYGVE Innovative Business Model, Expanding Its Footprint in the High-Value Asset Leasing Market

Health Canada Recognizes Ecosense And Its Industry-Leading Product Line

EcoQube, EcoBlu, and RadonEye are officially approved as trusted radon detection solutions by Health Canada.

San Jose, California – December 5, 2025 – Ecosense®, the industry leader in continuous radon monitoring, proudly announces that its consumer-grade Ecosense Digital Radon Monitors have been included on Health Canada’s approved list of long-term radon testing devices. This milestone highlights Ecosense’s commitment to enhancing radon safety and community well-being by delivering state-of-the-art detection and monitoring solutions for both consumers and professionals. Recognized as a top performer on Health Canada’s List of Approved Devices, Ecosense earned this distinction based on the 2023 C-NRPP Intercomparison studies.

“Getting approved by Health Canada is a major achievement for Ecosense,” said Insoo Park, Founder & CEO at Ecosense Inc. “Ecosense applauds Health Canada’s forward-thinking, proactive, and pragmatic decision to recognize the capability of consumer-grade devices for long-term radon testing and monitoring. This recognition highlights the precision, trustworthiness, and creativity of our products. Our goal has continuously been to equip individuals and families with the resources to manage their home radon levels and protect their well-being.” 

In November, Health Canada’s Radon Action Month raised awareness about radon risks and promoted home safety. The updated Residential Measurement Guide now approves consumer-grade electronic radon monitors for home use. Ecosense is proud to have three monitors — EcoBlu, EcoQube, and RadonEye — on Health Canada’s approved list, recognized for their accuracy and reliability through rigorous C-NRPP testing.

Health Canada regards radon testing as crucial to reducing the health hazards linked to long-term radon gas exposure, which is known to be the number one reason for lung cancer in nonsmokers. Radon awareness is on the rise. Ecosense is committed to offering high-quality solutions for both commercial and residential requirements. The company invites you to learn more about Ecosense and its product range by visiting its website at www.ecosense.io or checking out what it offers on Amazon’s platform. 

About Ecosense®

Based in the heart of Silicon Valley, Ecosense® is a leader and a trusted provider of both professional and consumer radon detection and monitoring solutions that are easy to use, accurate, and fast. The company’s intelligent real-time radon detectors utilize a patented detection technology with high accuracy, delivering reliable results in minutes, not days. Ecosense’s flagship monitoring product, EcoQube®, was named to TIME’s List of the 100 Best Inventions of 2021 and recognized as a CES 2021 Innovation Awards Honoree in the health and wellness category. Ecosense’s patented ion chamber technology performance has received independent validation from the University of Michigan (Dept. of Nuclear Engineering and Radiological Science) and the Kansas State University Radon Chamber. Both studies concluded that Ecosense’s Patented Technology performed comparably to premium research-grade detectors. Additionally, the 2023 Canadian National Radon Proficiency Program (C-NRPP) study on the intercomparison of consumer continuous radon monitors positioned Ecosense® as the industry leader in accurate and precise radon detection.

Media Contact
Company Name: Otter PR
Contact Person: Thomas Mustac
Email: Send Email
Address:100 E Pine St Suite 110
City: Orlando
State: Florida
Country: United States
Website: OtterPR.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Health Canada Recognizes Ecosense And Its Industry-Leading Product Line

Huntington’s Disease Market Report 2034: Epidemiology Insights, Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Companies – Prilenia Therapeutics, Neurocrine Biosciences, SOM Biotech, Anne

“Huntington’s Disease Market Report 2034”
The treatment for Huntington’s disease is complex as there exists no cure for Huntington’s disease, and there are no treatments known to slow or reverse its process. The current treatment available is symptoms specific, with the treatment goal to slow down the course of the disease and help affected people function for as long and as comfortably as possible.

DelveInsight’s “Huntington’s Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Huntington’s Disease, historical and forecasted epidemiology as well as the Huntington’s Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. 

To Know in detail about the Huntington’s Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Huntington’s Disease Market Forecast

Some of the key facts of the Huntington’s Disease Market Report: 

  • The Huntington’s Disease Market Size is anticipated to increase with a notable CAGR of 9.05% during the forecast period, 2023–2034

  • Key Huntington’s Disease Companies: Prilenia Therapeutics, Neurocrine Biosciences, SOM Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics, UniQure Biopharma, Wave life sciences, Takeda, Medesis Pharma, and others

  • Key Huntington’s Disease Therapies: Pridopidine, Tominersen, and others

  • Huntington’s disease (HD) is an incurable, rare genetic, progressive neurodegenerative disorder that causes death of brain cells, termed as neurons, in several areas of the brain, comprising those that help control voluntary (intentional) movement.

  • As per DelveInsight’s estimates, the total prevalent cases of Huntington’s disease were more than 81,000 in seven major markets.

  • The treatment for Huntington’s disease is complex as there exists no cure for Huntington’s disease, and there are no treatments known to slow or reverse its process. The current treatment available is symptoms specific, with the treatment goal to slow down the course of the disease and help affected people function for as long and as comfortably as possible.

  • Currently, the treatment strategies include the usage of many medications to treat specific symptoms such as medicines for depression, mood swings, and involuntary/abnormal movements and behaviors. The US FDA has approved AUSTEDO (deutetrabenazine) and XENAZINE (tetrabenazine) for the treatment of chorea associated with Huntington’s disease.

  • In August 2023, the US FDA approved INGREZZA (valbenazine) capsules for the treatment of adults with chorea associated with Huntington’s disease.

  • The United States accounted for the largest market size (more than 70% of the 7MM) of Huntington’s disease, in comparison to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

  • During the forecast period (2024–2034), pipeline candidates such as pridopidine, ANX005, and others are expected to drive the growth of Huntington’s disease treatment market size. Some of these treatments are addressing important areas of unmet medical need, i.e., lack of disease-modifying options for the treatment.

  • The growth of the Huntington’s disease market is expected to be mainly driven by entry of innovative emerging therapies, rising prevalence, increasing initiatives for R&D, and the advent of genetic testing.

  • The Huntington’s Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Huntington’s Disease pipeline products will significantly revolutionize the Huntington’s Disease market dynamics.

 

Huntington’s Disease Overview

Huntington’s disease (HD) is a progressive neurodegenerative disorder affecting nerve cells in the brain. It stems from a genetic mutation in the HTT gene, leading to the production of an abnormal huntingtin protein that accumulates in the basal ganglia and cerebral cortex, causing gradual brain damage.

 

Symptoms of Huntington’s disease typically appear between ages 30 and 50, though onset can occur earlier or later. These symptoms include involuntary movements known as chorea, often the initial noticeable signs. Cognitive impairments such as memory loss, difficulty concentrating, and decision-making challenges, along with psychiatric symptoms like depression, anxiety, and irritability, are also common.

 

As the disease advances, motor symptoms worsen, including rigidity, dystonia, and coordination issues. Cognitive and psychiatric symptoms may also deteriorate, significantly impacting daily life and quality of life.

 

Huntington’s disease is inherited in an autosomal dominant pattern, with a 50% chance of passing the mutated gene to offspring. Genetic testing allows early detection and proactive symptom management.

 

Currently, no cure exists for Huntington’s disease. Treatment focuses on symptom management and improving quality of life through medications, therapies, and support services. Ongoing research aims to develop disease-modifying treatments, offering hope for future advancements in managing this debilitating condition.

 

Huntington’s Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Huntington’s Disease Epidemiology Segmentation:

The Huntington’s Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Huntington’s Disease

  • Prevalent Cases of Huntington’s Disease by severity

  • Gender-specific Prevalence of Huntington’s Disease

  • Diagnosed Cases of Episodic and Chronic Huntington’s Disease

Download the report to understand which factors are driving Huntington’s Disease epidemiology trends @ Huntington’s Disease Epidemiology Forecast

Huntington’s Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Huntington’s Disease market or expected to get launched during the study period. The analysis covers Huntington’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Huntington’s Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Huntington’s Disease Therapies

  • Pridopidine

  • Tominersen

Huntington’s Disease Key Companies

  • Prilenia Therapeutics

  • Neurocrine Biosciences

  • SOM Biotech

  • Annexon Biosciences

  • Vaccinex

  • Sage Therapeutics

  • UniQure Biopharma

  • Wave life sciences

  • Takeda

  • Medesis Pharma

Discover more about therapies set to grab major Huntington’s Disease market share @ Huntington’s Disease Treatment Landscape

Scope of the Huntington’s Disease Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Huntington’s Disease Companies: Prilenia Therapeutics, Neurocrine Biosciences, SOM Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics, UniQure Biopharma, Wave life sciences, Takeda, Medesis Pharma, and others

  • Key Huntington’s Disease Therapies: Pridopidine, Tominersen, and others

  • Huntington’s Disease Therapeutic Assessment: Huntington’s Disease current marketed and Huntington’s Disease emerging therapies

  • Huntington’s Disease Market Dynamics: Huntington’s Disease market drivers and Huntington’s Disease market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Huntington’s Disease Unmet Needs, KOL’s views, Analyst’s views, Huntington’s Disease Market Access and Reimbursement 

Table of Contents 

1. Huntington’s Disease Market Report Introduction

2. Executive Summary for Huntington’s Disease

3. SWOT analysis of Huntington’s Disease

4. Huntington’s Disease Patient Share (%) Overview at a Glance

5. Huntington’s Disease Market Overview at a Glance

6. Huntington’s Disease Disease Background and Overview

7. Huntington’s Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Huntington’s Disease 

9. Huntington’s Disease Current Treatment and Medical Practices

10. Huntington’s Disease Unmet Needs

11. Huntington’s Disease Emerging Therapies

12. Huntington’s Disease Market Outlook

13. Country-Wise Huntington’s Disease Market Analysis (2020–2034)

14. Huntington’s Disease Market Access and Reimbursement of Therapies

15. Huntington’s Disease Market Drivers

16. Huntington’s Disease Market Barriers

17.  Huntington’s Disease Appendix

18. Huntington’s Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports: 

Huntington’s Disease Pipeline  

“Huntington’s Disease Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Huntington’s Disease market. A detailed picture of the Huntington’s Disease pipeline landscape is provided, which includes the disease overview and Huntington’s Disease treatment guidelines. 

Huntington’s Disease Epidemiology 

DelveInsight’s ‘Huntington’s Disease Epidemiology Forecast to 2034’ report delivers an in-depth understanding of the disease, historical and forecasted Huntington’s Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Huntington’s Disease Market Report 2034: Epidemiology Insights, Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Companies – Prilenia Therapeutics, Neurocrine Biosciences, SOM Biotech, Anne

Her2+ Gastric Cancer Market Report 2032: Epidemiology Insights, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, Daiichi Sa

“Her2+ Gastric Cancer Market Report 2032”
DelveInsight’s “HER2+ Gastric Cancer Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the HER2+ Gastric Cancer, historical and forecasted epidemiology as well as the HER2+ Gastric Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s “Her2+ Gastric Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Her2+ Gastric Cancer, historical and forecasted epidemiology as well as the Her2+ Gastric Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Her2+ Gastric Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Her2+ Gastric Cancer Market Forecast

Some of the key facts of the Her2+ Gastric Cancer Market Report: 

  • The Her2+ Gastric Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032).

  • Key Her2+ Gastric Cancer Companies: Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, Daiichi Sankyo Inc., Genentech, Bayer, Loxo Oncology, Eli Lilly, Remegen Biosciences, AstraZeneca, Hutchison Medipharma Limited, Jiangsu Alphamab Biopharmaceuticals, LintonPharm, Qilu Pharmaceutical Co., Shanghai Henlius Biotech, Bayer, Bristol-Myers Squibb, Ono Pharmaceutical, Jiangsu HengRui Medicine, Seagen, MacroGenics, Zai Lab, Merck Sharp & Dohme Corp., Eisai Inc., Merus N.V., OncXerna Therapeutics, Innovent Biologics, and others

  • Key Her2+ Gastric Cancer Therapies: SHR-A1811, Cinrebafusp alfa, BI-1607, and others

  • In November 2023, Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) granted Breakthrough Therapy designation to KN026, a HER2 bispecific antibody, in combination with chemotherapy for the treatment of HER2-positive gastric cancer, including gastroesophageal junction cancer. This designation underscores the potential of KN026 as a promising treatment option for this aggressive cancer type, expediting its development and regulatory review process.

  • In December 2022, AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) was approved by the European Union (EU) as a monotherapy for adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have previously undergone a trastuzumab-based regimen. This approval provides a significant new treatment option for patients with advanced HER2-positive gastric cancer who have limited therapeutic alternatives.

  • The Her2+ Gastric Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Her2+ Gastric Cancer pipeline products will significantly revolutionize the Her2+ Gastric Cancer market dynamics.

Her2+ Gastric Cancer Overview

HER2-positive gastric cancer, also known as HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, is a specific type of stomach cancer characterized by the overproduction of the human epidermal growth factor receptor 2 (HER2) protein. This form of cancer represents a significant proportion of gastric cancer cases and is associated with distinct clinical and pathological features.

HER2 plays a key role in regulating cell growth and division under normal conditions. However, in HER2-positive gastric cancer, the overexpression of this protein leads to uncontrolled cell proliferation, contributing to the formation and growth of tumors.

The identification of HER2 overexpression in gastric cancer has had a profound impact on treatment strategies, as therapies targeting HER2 have shown the ability to improve patient outcomes. These treatments are specifically designed to block the HER2 protein’s activity, disrupting the signals that drive cancer cell growth and survival.

Key therapeutic options for HER2-positive gastric cancer include:

1. HER2-Targeted Therapy: Central to the treatment of HER2-positive gastric cancer is the use of HER2-targeted therapies such as trastuzumab (Herceptin), pertuzumab, and trastuzumab deruxtecan. These therapies are often combined with chemotherapy and have been shown to improve both overall survival and progression-free survival in patients with this cancer subtype.

2. Chemotherapy: Chemotherapy is commonly used alongside HER2-targeted therapies and includes drugs such as fluoropyrimidines, platinum-based agents, and taxanes. These chemotherapy agents help enhance the effectiveness of treatment and manage cancer progression.

3. Surgical Intervention: For patients with localized or resectable HER2-positive gastric cancer, surgery may be an option. This involves the removal of the tumor and nearby lymph nodes. Post-surgery, adjuvant chemotherapy or HER2-targeted therapy may be administered to reduce the risk of recurrence.

4. Radiation Therapy: In cases of locally advanced or inoperable HER2-positive gastric cancer, radiation therapy may be used, often in combination with chemotherapy or surgery, to shrink tumors and destroy cancer cells.

Effective management of HER2-positive gastric cancer requires a multidisciplinary approach, involving oncologists, surgeons, and radiation oncologists. Treatment plans are customized to the individual, considering factors such as the tumor’s stage, the patient’s overall health, and the treatment goals.

Thanks to the early detection of HER2-positive gastric cancer and the availability of HER2-targeted therapies, patient outcomes have significantly improved. However, ongoing research is critical to refine treatment strategies and further enhance long-term survival rates.

Her2+ Gastric Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Her2+ Gastric Cancer Epidemiology Segmentation:

The Her2+ Gastric Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Her2+ Gastric Cancer

  • Prevalent Cases of Her2+ Gastric Cancer by severity

  • Gender-specific Prevalence of Her2+ Gastric Cancer

  • Diagnosed Cases of Episodic and Chronic Her2+ Gastric Cancer

Download the report to understand which factors are driving Her2+ Gastric Cancer epidemiology trends @ Her2+ Gastric Cancer Epidemiology Forecast

Her2+ Gastric Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Her2+ Gastric Cancer market or expected to get launched during the study period. The analysis covers Her2+ Gastric Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Her2+ Gastric Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Her2+ Gastric Cancer Therapies 

  • SHR-A1811, Cinrebafusp alfa, BI-1607, and others.

Her2+ Gastric Cancer Key Companies

  • Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, Daiichi Sankyo Inc., Genentech, Bayer, Loxo Oncology, Eli Lilly, Remegen Biosciences, AstraZeneca, Hutchison Medipharma Limited, Jiangsu Alphamab Biopharmaceuticals, LintonPharm, Qilu Pharmaceutical Co., Shanghai Henlius Biotech, Bayer, Bristol-Myers Squibb, Ono Pharmaceutical, Jiangsu HengRui Medicine, Seagen, MacroGenics, Zai Lab, Merck Sharp & Dohme Corp., Eisai Inc., Merus N.V., OncXerna Therapeutics, Innovent Biologics, and others.

Discover more about therapies set to grab major Her2+ Gastric Cancer market share @ Her2+ Gastric Cancer Treatment Landscape

Scope of the Her2+ Gastric Cancer Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Her2+ Gastric Cancer Companies: Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, Daiichi Sankyo Inc., Genentech, Bayer, Loxo Oncology, Eli Lilly, Remegen Biosciences, AstraZeneca, Hutchison Medipharma Limited, Jiangsu Alphamab Biopharmaceuticals, LintonPharm, Qilu Pharmaceutical Co., Shanghai Henlius Biotech, Bayer, Bristol-Myers Squibb, Ono Pharmaceutical, Jiangsu HengRui Medicine, Seagen, MacroGenics, Zai Lab, Merck Sharp & Dohme Corp., Eisai Inc., Merus N.V., OncXerna Therapeutics, Innovent Biologics, and others

  • Key Her2+ Gastric Cancer Therapies: SHR-A1811, Cinrebafusp alfa, BI-1607, and others

  • Her2+ Gastric Cancer Therapeutic Assessment: Her2+ Gastric Cancer current marketed and Her2+ Gastric Cancer emerging therapies

  • Her2+ Gastric Cancer Market Dynamics: Her2+ Gastric Cancer market drivers and Her2+ Gastric Cancer market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Her2+ Gastric Cancer Unmet Needs, KOL’s views, Analyst’s views, Her2+ Gastric Cancer Market Access and Reimbursement 

Table of Contents 

1. Her2+ Gastric Cancer Market Report Introduction

2. Executive Summary for Her2+ Gastric Cancer

3. SWOT analysis of Her2+ Gastric Cancer

4. Her2+ Gastric Cancer Patient Share (%) Overview at a Glance

5. Her2+ Gastric Cancer Market Overview at a Glance

6. Her2+ Gastric Cancer Disease Background and Overview

7. Her2+ Gastric Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Her2+ Gastric Cancer 

9. Her2+ Gastric Cancer Current Treatment and Medical Practices

10. Her2+ Gastric Cancer Unmet Needs

11. Her2+ Gastric Cancer Emerging Therapies

12. Her2+ Gastric Cancer Market Outlook

13. Country-Wise Her2+ Gastric Cancer Market Analysis (2019–2032)

14. Her2+ Gastric Cancer Market Access and Reimbursement of Therapies

15. Her2+ Gastric Cancer Market Drivers

16. Her2+ Gastric Cancer Market Barriers

17.  Her2+ Gastric Cancer Appendix

18. Her2+ Gastric Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports: 

Her2+ Gastric Cancer Pipeline  

“Her2+ Gastric Cancer Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Her2+ Gastric Cancer market. A detailed picture of the Her2+ Gastric Cancer pipeline landscape is provided, which includes the disease overview and Her2+ Gastric Cancer treatment guidelines. 

Her2+ Gastric Cancer Epidemiology 

DelveInsight’s ‘Her2+ Gastric Cancer Epidemiology Forecast to 2032’ report delivers an in-depth understanding of the disease, historical and forecasted Her2+ Gastric Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Her2+ Gastric Cancer Market Report 2032: Epidemiology Insights, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, Daiichi Sa

Dystrophic Epidermolysis Bullosa Market expected to rise, DelveInsight | Phoenix Tissue Repair, Castle Creek Biosciences, Phoenicis Therapeutics, Aegle Therapeutics, RHEACELL, Anterogen

“Dystrophic Epidermolysis Bullosa Market”
The Dystrophic Epidermolysis Bullosa market report covers a segment of key events, an executive summary, descriptive overview of Dystrophic Epidermolysis Bullosa (DEB), explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.

The Dystrophic Epidermolysis Bullosa market growth is driven by factors like increase in the prevalence of Dystrophic Epidermolysis Bullosa, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Dystrophic Epidermolysis Bullosa market report also offers comprehensive insights into the Dystrophic Epidermolysis Bullosa market size, share, Dystrophic Epidermolysis Bullosa epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Dystrophic Epidermolysis Bullosa market size growth forward. 

Some of the key highlights from the Dystrophic Epidermolysis Bullosa Market Insights Report:

  • Epidermolysis Bullosa (EB) refers to a group of rare, inherited disorders caused by mutations in various skin structural proteins. These mutations impact around 15 different genes that are essential for skin integrity. EB is classified into multiple subtypes based on the location of the affected proteins and the level of blistering that occurs. 

  • Dystrophic Epidermolysis Bullosa (DEB) is primarily divided into six types: dominant DEB (DDEB), recessive DEB (RDEB), RDEB-generalized severe (GS), RDEB-generalized intermediate (GI), RDEB-unknown subtypes, and RDEB-other.

  • In 2023, the total diagnosed prevalent cases of DEB in the 7MM were approximately 6,500, with the highest number of cases observed in the United States (around 3,500 cases, or nearly 50% of the total).

  • On November 12, 2024, Abeona Therapeutics Inc. (Nasdaq: ABEO) announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted Biologics License Application (BLA) for prademagene zamikeracel (pz-cel), an investigational autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). The FDA has set a target action date of April 29, 2025, under the Prescription Drug User Fee Act (PDUFA).

  • The DEB market is expected to experience significant growth, driven by the anticipated approval of one-time gene therapies and increased awareness of the condition. The total market size for DEB in the 7MM was valued at approximately USD 550 million in 2023 and is expected to continue rising during the forecast period.

  • The United States holds the largest market share for Dystrophic Epidermolysis Bullosa (DEB) when compared to the EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan. 

  • Currently, VYJUVEK and FILSUVEZ are the only approved treatments for DEB. Existing management strategies primarily focus on providing symptomatic relief, such as pain and itch management, treating chronic wounds and infections, and preventing complications when possible.

  • The DEB pipeline includes promising therapies like D-Fi (FCX-007), ALLO-ASC-SHEET, and others. 

  • Prevalence data by disease severity indicates that moderate forms of DEB are significantly more common than severe cases.

Strategise your business goals by understanding market dynamics @ Dystrophic Epidermolysis Bullosa Market Landscape

Dystrophic Epidermolysis Bullosa Overview 

Dystrophic Epidermolysis Bullosa (DEB) is one of the major subtypes of Epidermolysis Bullosa (EB), a group of skin disorders characterized by varying degrees of fragility in the skin and mucous membranes. This fragility occurs due to the absence, reduction, or abnormality of proteins crucial for maintaining skin integrity. EB is classified into four main types based on the layer of the skin where blisters form: EB simplex (EBS; blister formation within the epidermal layer), junctional EB (JEB; within the lamina lucida of the basement membrane), dystrophic EB (DEB; below the basement membrane), and Kindler’s EB (KEB; mixed skin cleavage pattern).

The diagnosis of DEB is confirmed in individuals with characteristic clinical features and the identification of pathogenic variants in the **COL7A1** gene—biallelic variants for recessive DEB (RDEB) or a heterozygous variant for dominant DEB (DDEB)—through molecular genetic testing. If molecular testing fails to provide a diagnosis, a skin biopsy with direct immunofluorescence (IF) for specific markers and/or electron microscopy (EM) may be required, as routine histology is generally not helpful.

Current therapeutic strategies for DEB focus on advanced wound care and minimizing the factors that trigger blistering and hinder healing. Key approaches include maintaining high hygiene standards, intensive moisturizing, and careful skin care. Blisters typically heal well with proper daily care, such as disinfection using effective aqueous disinfectants. Avoiding adhesives and compressive dressings is essential to prevent further blister formation. Silicon-based wound care products are particularly useful for delicate or difficult-to-treat skin areas. While systemic therapy is generally not needed, short-term use of antibiotics or corticosteroids may be necessary in certain cases. For severely affected individuals with extra-cutaneous involvement, multidisciplinary management—engaging pediatricians, dermatologists, and other specialists—is crucial for optimal care.

Do you know the treatment paradigms for different countries? Download our Dystrophic Epidermolysis Bullosa Market Sample Report

Dystrophic Epidermolysis Bullosa Epidemiology Insights:

  • In 2023, the United States had the highest number of prevalent cases of Dystrophic Epidermolysis Bullosa (DEB) among the 7MM, with a total of approximately 3,500 cases. 

  • The age group most affected by DEB in 2023 was children between 1 and 9 years old, accounting for about 1,300 cases. 

  • Among the EU4 countries (Germany, France, Italy, Spain) and the UK, the United Kingdom reported the highest proportion of DEB cases, representing around 33% of the total cases in the region.

  • Approximately 48% of DEB cases in 2023 were categorized as moderate in severity.

Dystrophic Epidermolysis Bullosa Epidemiology Segmentation 

DelveInsight’s Dystrophic Epidermolysis Bullosa market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Dystrophic Epidermolysis Bullosa historical patient pools and forecasted Dystrophic Epidermolysis Bullosa patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Dystrophic Epidermolysis Bullosa Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

  • Dystrophic Epidermolysis Bullosa Prevalence 

  • Age-Specific Dystrophic Epidermolysis Bullosa Prevalence 

  • Gender-Specific Dystrophic Epidermolysis Bullosa Prevalence 

  • Diagnosed and Treatable Cases of Dystrophic Epidermolysis Bullosa

Visit for more @ Dystrophic Epidermolysis Bullosa Epidemiological Insights

Recent Breakthroughs in the Dystrophic Epidermolysis Bullosa Market

  • FDA Approves First Gene Therapy for Dystrophic Epidermolysis Bullosa (DEB)

  • Vyjuvek is the first FDA-approved gene therapy for dystrophic epidermolysis bullosa (DEB) and the first topical gene therapy approved in the U.S. It’s indicated for use in patients 6 months of age or older.

Dystrophic Epidermolysis Bullosa Treatment Market 

The Dystrophic Epidermolysis Bullosa market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Dystrophic Epidermolysis Bullosa market trends by analyzing the impact of current Dystrophic Epidermolysis Bullosa therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Dystrophic Epidermolysis Bullosa market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Dystrophic Epidermolysis Bullosa market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Dystrophic Epidermolysis Bullosa market in 7MM is expected to witness a major change in the study period 2020-2034.

Dystrophic Epidermolysis Bullosa Market Insights

  • In 2023, the United States held the largest market share for DEB, with a market size of approximately USD 400 million among the 7MM. 

  • Among the EU4 and the UK, the UK represented the highest market size at around USD 50 million for DEB. 

  • Spain had the smallest market size in the 7MM, estimated at approximately USD 20 million. DelveInsight’s analysis forecasts market growth driven by the launch of emerging therapies.

Dystrophic Epidermolysis Bullosa Emerging Drugs

PTR-01: Phoenix Tissue Repair

Phoenix Tissue Repair is advancing an investigational therapy known as PTR-01, a systemic recombinant collagen type VII (rC7) for the treatment of Recessive Dystrophic Epidermolysis Bullosa. rC7 is a potentially disease-modifying drug that is delivered intravenously to patients, replacing defective collagen type VII with healthy collagen at the sites where it is needed both internally and externally. Phoenix Tissue Repair acquired worldwide rights to PTR-01 from Shire Plc in 2017 and has initiated its first clinical trial. Preclinical studies of PTR-01 have shown that it selectively anchors in the skin and other tissues affected by an absence of collagen type VII. In four animal models of the disease, intravenous injections of PTR-01 promoted healing of DEB wounds. These experiments have shown improvements in tissue structure, disease presentation and survival, indicating a restoration of natural skin architecture.

FCX-007: Castle Creek Biosciences

D-Fi, also known as FCX-007, (dabocemagene autoficel), is being developed as an ex vivo, autologous cell-based gene therapy to address the deficiency of functional COL7 in patients with dystrophic epidermolysis bullosa (DEB). D-Fi has been clinically studied in a Phase 1/2 clinical study (NCT02810951), which assessed 6 patients with RDEB. In this study, 80% (8/10) of treated chronic wounds demonstrated complete wound healing 12 weeks after the first injection of D-Fi, while none of the untreated wounds were healed. D-Fi was well tolerated post-administration with few reports of temporary redness or discoloration at the injection site. D-Fi is currently in Phase 3 clinical development for the localized treatment of chronic wounds in individuals with RDEB.

Dystrophic Epidermolysis Bullosa Key Companies

  • Phoenix Tissue Repair

  • Castle Creek Biosciences

  • Phoenicis Therapeutics

  • Aegle Therapeutics

  • RHEACELL GmbH & Co. KG

  • Anterogen Co., Ltd.

  • Abeona Therapeutics, Inc

  • InMed Pharmaceuticals

  • BridgeBio Inc.

  • Eloxx Pharmaceuticals

  • Relief Therapeutics

  • Quoin Pharmaceuticals

For more information, visit Dystrophic Epidermolysis Bullosa Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Dystrophic Epidermolysis Bullosa Market Report:

  • 11 Years Forecast

  • 7MM Coverage 

  • Descriptive overview of Dystrophic Epidermolysis Bullosa, causes, signs and symptoms, diagnosis, treatment

  • Comprehensive insight into Dystrophic Epidermolysis Bullosa epidemiology in the 7MM

  • Dystrophic Epidermolysis Bullosa marketed and emerging therapies 

  • Dystrophic Epidermolysis Bullosa companies

  • Dystrophic Epidermolysis Bullosa market drivers and barriers 

Key Questions Answered in the Dystrophic Epidermolysis Bullosa Market Report 2034:

  • What was the Dystrophic Epidermolysis Bullosa market share distribution in 2020, and how would it appear in 2034?

  • What is the total Dystrophic Epidermolysis Bullosa market size and the market size by therapy across the 7MM for the study period (2020-32)?

  • What are the important findings from 7MM, and which country will have the greatest Dystrophic Epidermolysis Bullosa market size from 2020-32?

  • During the study period (2020-2034), at what CAGR is the Dystrophic Epidermolysis Bullosa market projected to expand at 7MM?

Table of Contents:

1 Dystrophic Epidermolysis Bullosa Market Key Comprehensive Insights 

2 Dystrophic Epidermolysis Bullosa Market Report Introduction

3 Competitive Intelligence Analysis for Dystrophic Epidermolysis Bullosa

4 Dystrophic Epidermolysis Bullosa Market Analysis Overview at a Glance

5 Executive Summary of Dystrophic Epidermolysis Bullosa

6 Dystrophic Epidermolysis Bullosa Epidemiology and Market Methodology

7 Dystrophic Epidermolysis Bullosa Epidemiology and Patient Population

8 Dystrophic Epidermolysis Bullosa Patient Journey

9 Dystrophic Epidermolysis Bullosa Treatment Algorithm, Dystrophic Epidermolysis Bullosa Current Treatment, and Medical Practices

10 Key Endpoints in Dystrophic Epidermolysis Bullosa Clinical Trials

11 Dystrophic Epidermolysis Bullosa Marketed Therapies 

12 Dystrophic Epidermolysis Bullosa Emerging Therapies

13 Dystrophic Epidermolysis Bullosa: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Dystrophic Epidermolysis Bullosa

16 Dystrophic Epidermolysis Bullosa Market Key Opinion Leaders Reviews

18 Dystrophic Epidermolysis Bullosa Market Drivers

19 Dystrophic Epidermolysis Bullosa Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Dystrophic Epidermolysis Bullosa Epidemiology 2034

DelveInsight’s “Dystrophic Epidermolysis Bullosa – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Dystrophic Epidermolysis Bullosa epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Dystrophic Epidermolysis Bullosa Pipeline 2024

“Dystrophic Epidermolysis Bullosa Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Dystrophic Epidermolysis Bullosa market. A detailed picture of the Dystrophic Epidermolysis Bullosa pipeline landscape is provided, which includes the disease overview and Dystrophic Epidermolysis Bullosa treatment guidelines. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dystrophic Epidermolysis Bullosa Market expected to rise, DelveInsight | Phoenix Tissue Repair, Castle Creek Biosciences, Phoenicis Therapeutics, Aegle Therapeutics, RHEACELL, Anterogen

Cytokine Release Syndrome Market expected to rise, DelveInsight | Companies such as Novartis, Incyte Corporation, Olatec Therapeutics LLC, expected to drive market

“Cytokine Release Syndrome Market”
The Cytokine Release Syndrome market growth is driven by factors like increase in the prevalence of Cytokine Release Syndrome, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Cytokine Release Syndrome market report also offers comprehensive insights into the Cytokine Release Syndrome market size, share, Cytokine Release Syndrome epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Cytokine Release Syndrome market size growth forward. 

Some of the key highlights from the Cytokine Release Syndrome Market Insights Report:

  • Cytokine Release Syndrome (CRS) is a severe systemic inflammatory response often triggered by treatments like CAR T-cell therapy, therapeutic antibodies, and haploidentical allogeneic transplants. It is typically characterized by symptoms such as fever and multi-organ dysfunction.

  • The United States holds the largest share (85%) of the CRS treatment market, compared to the EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

  • Currently, ACTEMRA (tocilizumab) is the only approved therapy for CRS, although treatment often relies on off-label drugs. Several companies are actively investigating new treatment options, with key players like Incyte Corporation (with Itacitinib), Sobi Pharma (with Kineret), and others conducting clinical trials aimed at improving CRS management.

  • Among the emerging therapies, Itacitinib is anticipated to capture the largest market share by 2034 across the 7MM.

  • According to DelveInsight analysts, the majority of CRS cases (approximately 80% in 2023) are associated with allogeneic transplants in the 7MM.

Strategise your business goals by understanding market dynamics @ Cytokine Release Syndrome Market Landscape

Cytokine Release Syndrome Overview 

Cytokine Release Syndrome (CRS) is a systemic inflammatory response triggered by various factors, including infections and certain drugs, leading to the pathological over-activation of T cells. This, in turn, causes excessive cytokine release from T cells and other immune cells. CRS can also arise after certain immunotherapies, such as CAR T-cell therapy, and is sometimes referred to as a “cytokine storm” or “cytokine-associated toxicity.” Clinically, CRS is characterized by fever and malaise, which can progress quickly to capillary leak syndrome, hypotension, vasodilatory shock, hypoxia, and potentially death. The severity of CRS can vary, ranging from mild constitutional symptoms to a severe form that involves multi-organ dysfunction.

Currently, there are no established diagnostic criteria for CRS. An accurate diagnosis typically relies on three key elements: clinical symptoms, elevated biomarkers, and recent treatment with biological agents. While circulating cytokine levels could be used as biomarkers to diagnose and assess the severity of CRS, these tests are often costly and may not be readily available in all healthcare settings. C-reactive protein (CRP), produced by the liver in response to interleukin-6 (IL-6), is a reliable surrogate marker for IL-6 bioactivity. Measuring CRP is inexpensive, quick, and widely available, making it a practical tool for diagnosing and monitoring CRS in most hospitals.

This report on Cytokine Release Syndrome offers an in-depth overview of the pathophysiology, diagnostic approaches, and treatment algorithms for CRS. It also includes a real-world patient journey, detailing the progression from initial symptoms to diagnosis and treatment.

There is strong evidence suggesting that interleukin-6 (IL-6), which exhibits both anti-inflammatory and pro-inflammatory properties, plays a crucial role as a mediator in the signaling cascade of Cytokine Release Syndrome (CRS). In addition to its role in CRS, IL-6 may also be involved in initiating the body’s antitumor response.

In August 2017, the U.S. FDA approved ACTEMRA (tocilizumab) for the treatment of severe or life-threatening CRS induced by CAR T-cell therapy in patients aged 2 years and older. ACTEMRA is a humanized monoclonal antibody that acts as an IL-6 receptor antagonist, blocking both classic and trans-IL-6 signaling pathways on immune effector cells.

IL-6 has emerged as a key cytokine in exacerbating CRS, particularly in T-cell-engaging therapies. Depending on the clinical setting, both tocilizumab (an IL-6 receptor-targeting monoclonal antibody) and siltuximab (a chimeric anti-IL-6 monoclonal antibody) are used to manage CRS. In cases where toxicities are refractory to IL-6-targeting therapies, corticosteroids are often introduced. Typically, dexamethasone (10 mg/kg IV every 6 hours) or methylprednisolone (1 mg/kg IV every 12 hours) are administered for moderate to high-grade CRS.

Do you know the treatment paradigms for different countries? Download our Cytokine Release Syndrome Market Sample Report

Cytokine Release Syndrome Epidemiology Insights:

  • In 2023, DelveInsight estimates that approximately 30% of the total Cytokine Release Syndrome (CRS) cases in the 7MM occurred in the United States. 

  • Of the CRS cases in the United States, around 30% were attributed to treatments involving CAR-T therapies.

  • Grade 3-4 CRS cases accounted for approximately 18% of the total incident CRS cases in the 7MM in 2023, according to DelveInsight’s consultant estimates.

  • Among the EU4 countries and the UK, Germany reported the highest incidence of CRS cases, followed by France.

Cytokine Release Syndrome Epidemiology Segmentation 

DelveInsight’s Cytokine Release Syndrome market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Cytokine Release Syndrome historical patient pools and forecasted Cytokine Release Syndrome patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Cytokine Release Syndrome Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

  • Cytokine Release Syndrome Prevalence 

  • Age-Specific Cytokine Release Syndrome Prevalence 

  • Gender-Specific Cytokine Release Syndrome Prevalence 

  • Diagnosed and Treatable Cases of Cytokine Release Syndrome

Visit for more @ Cytokine Release Syndrome Epidemiological Insights

Cytokine Release Syndrome Market Insights:

  • The United States accounts for approximately 85% of the Cytokine Release Syndrome (CRS) market, surpassing the combined market size of the EU4, the UK, and Japan.

  • Among emerging therapies, Itacitinib is projected to capture the largest market share (51%) by 2034 across the 7MM.

  • According to DelveInsight’s forecasts, Germany is expected to hold the second-largest market share for CRS treatment during the 2024–2034 period.

Cytokine Release Syndrome Treatment Market 

The Cytokine Release Syndrome market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Cytokine Release Syndrome market trends by analyzing the impact of current Cytokine Release Syndrome therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Cytokine Release Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Cytokine Release Syndrome market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Cytokine Release Syndrome market in 7MM is expected to witness a major change in the study period 2020-2034.

Cytokine Release Syndrome Key Companies

  • Novartis

  • Incyte Corporation

  • Olatec Therapeutics LLC

  • And others

Cytokine Release Syndrome Pipeline Therapies

  • Canakinumab

  • Itacitinib

  • Dapansutrile

  • And others

Cytokine Release Syndrome Pipeline Analysis: Drug Profile

Canakinumab: Novartis

Canakinumab is an interleukin (IL)-1β blocker indicated to treat certain periodic fever syndromes, such as cryopyrin-associated periodic syndromes and systemic juvenile idiopathic arthritis. Novartis is conducting a phase III trial, called CAN-COVID which will evaluate the drug’s efficacy in treating a type of severe immune overreaction called cytokine release syndrome (CRS) related to Covid-19 pneumonia.

For more information, visit Cytokine Release Syndrome Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Cytokine Release Syndrome Market Report:

  • 11 Years Forecast

  • 7MM Coverage 

  • Descriptive overview of Cytokine Release Syndrome, causes, signs and symptoms, diagnosis, treatment

  • Comprehensive insight into Cytokine Release Syndrome epidemiology in the 7MM

  • Cytokine Release Syndrome marketed and emerging therapies 

  • Cytokine Release Syndrome companies

  • Cytokine Release Syndrome market drivers and barriers 

Key Questions Answered in the Cytokine Release Syndrome Market Report 2034:

  • What was the Cytokine Release Syndrome market share distribution in 2020, and how would it appear in 2034?

  • What is the total Cytokine Release Syndrome market size and the market size by therapy across the 7MM for the study period (2020-32)?

  • What are the important findings from 7MM, and which country will have the greatest Cytokine Release Syndrome market size from 2020-32?

  • During the study period (2020-2034), at what CAGR is the Cytokine Release Syndrome market projected to expand at 7MM?

Table of Contents:

1 Cytokine Release Syndrome Market Key Comprehensive Insights 

2 Cytokine Release Syndrome Market Report Introduction

3 Competitive Intelligence Analysis for Cytokine Release Syndrome

4 Cytokine Release Syndrome Market Analysis Overview at a Glance

5 Executive Summary of Cytokine Release Syndrome

6 Cytokine Release Syndrome Epidemiology and Market Methodology

7 Cytokine Release Syndrome Epidemiology and Patient Population

8 Cytokine Release Syndrome Patient Journey

9 Cytokine Release Syndrome Treatment Algorithm, Cytokine Release Syndrome Current Treatment, and Medical Practices

10 Key Endpoints in Cytokine Release Syndrome Clinical Trials

11 Cytokine Release Syndrome Marketed Therapies 

12 Cytokine Release Syndrome Emerging Therapies

13 Cytokine Release Syndrome: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Cytokine Release Syndrome

16 Cytokine Release Syndrome Market Key Opinion Leaders Reviews

18 Cytokine Release Syndrome Market Drivers

19 Cytokine Release Syndrome Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Cytokine Release Syndrome Epidemiology 2034

DelveInsight’s “Cytokine Release Syndrome – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Cytokine Release Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Cytokine Release Syndrome Pipeline 2023

“Cytokine Release Syndrome Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Cytokine Release Syndrome market. A detailed picture of the Cytokine Release Syndrome pipeline landscape is provided, which includes the disease overview and Cytokine Release Syndrome treatment guidelines. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cytokine Release Syndrome Market expected to rise, DelveInsight | Companies such as Novartis, Incyte Corporation, Olatec Therapeutics LLC, expected to drive market

CareLink360 Appoints Senior Brain And Cognitive Scientist To Its Board Of Advisors

CareLink360 Appoints Dr. Newton Howard to its Board of Advisors.

Flemington, NJ – December 5, 2024 – CareLink360 today announced that Dr. Newton Howard, Veteran Brain and Cognitive Scientist, Founder and Former Director of the Massachusetts Institute of Technology (MIT) Mind Machine Project, and professor of Computational Neurology and Functional Neurosurgery at Georgetown University will join its Board of Advisors effective December 5.

Dr. Howard, a well-respected global entrepreneur, and health industry veteran with deep research and operational experience in Cognition, Memory, Trauma, Machine Learning, Comprehensive Brain Modeling, Natural Language Processing, Nanotech, Medical Devices and Artificial Intelligence will advise CareLink360 in building out and scaling their global cognitive solutions and eco-system for aging adults including those living with Alzheimer’s Disease, Dementia, or Mild Cognitive Impairment, their caregivers, healthcare professionals, and extended care teams.  

“It is an honor to welcome Dr. Howard to the CareLink360 Advisory Board,” said David Duplay, Chairman & Chief Executive Officer, CareLink360. “Dr. Howard’s extensive background in launching and scaling the Brain Sciences Foundation (BSF), an organization with the goal of improving the quality of life for those suffering from neurological disorders perfectly aligns with the CareLink360 mission of Changing The Way The World Ages through our cognitive solutions for aging adults in addition to our ability to deliver Social Nutrition through Virtual Social Therapy,” added Duplay.

“I am honored to join the CareLink360 Advisory Board and look forward to working with Dave and his extraordinarily talented team of executives and fellow board members.  CareLink360 provides a much needed and life changing solution set to a vulnerable and rapidly growing global aging population, their families, caregivers, and extended care teams. With CareLink360’s brain fitness activities, health and wellness education, important medication and other reminders, along with the ability to track and measure cognitive stability and/or cognitive decline over time through ALBERTai, CareLink360 is an important solution to facilitate shared decision making between aging loved ones and their healthcare professionals,” said Dr. Howard.

“CareLink360 is an innovative quality of life eco-system and solution set for the significant and growing global population of aging adults, along with people living with mental health and other cognitive conditions or physical limitations.  In addition to the aging population, CareLink360 provides Social Nutrition to adult children living with mental health challenges whose family limit or prohibit their access to the internet because of their vulnerability to the negative influences and predators targeting this population of our society” stated Dr. Howard. 

About CareLink360

At CareLink360, our mission is to Change to The Way The World Ages by being the global leader in assisting our clients to deliver high-quality, person-and-patient centered care across the care continuum; through our integrated, patented, and easy to use Digital Health Companion. We strive to mitigate the global epidemic of isolation and loneliness which affects people of all ages, races, gender, and socioeconomic backgrounds. The current competitive landscape consists of browser and web-based applications which require a base knowledge of user technology. The CareLink360 Digital Health Companion, is currently the single device in the market that was designed from the ground up to accommodate non-technical users and is protected under four US patents.

About Dr. Newton Howard

Dr. Newton Howard is a brain and cognitive scientist, the former founder and director of the MIT Mind Machine Project at the Massachusetts Institute of Technology (MIT). He is a professor of computational neurology and functional neurosurgery at Georgetown University. He was a professor of at the University of Oxford, where he directed the Oxford Computational Neuroscience Laboratory.  

Dr. Howard is also the director of MIT’s Synthetic Intelligence Lab, the founder of the Center for Advanced Defense Studiesand the chairman of the Brain Sciences Foundation. Professor Howard is also a senior fellow at the John Radcliffe Hospital at Oxford, a senior scientist at INSERM in Paris and a P.A.H. at the CHU Hospital in Martinique.

His research areas include Cognition, Memory, Trauma, Machine Learning, Comprehensive Brain Modeling, Natural Language Processing, Nanotech, Medical Devices and Artificial Intelligence.

Howard earned his B.A. from Concordia University Ann Arbor and an M.A. in Technology from Eastern Michigan University. He went on to study at MIT and at the University of Oxford where, as a graduate member of the Faculty of Mathematical Sciences, he proposed the Theory of Intention Awareness (IA). Dr. Howard also received a Doctorate in Cognitive Informatics and Mathematics from the University of Paris-Sorbonne, where he was also awarded a Habilitation a Diriger des Recherches for his work on the Physics of Cognition (PoC).

Media Contact
Company Name: CareLink360
Contact Person: David Duplay
Email: Send Email
City: Flemington
State: NJ
Country: United States
Website: www.MyCareLink360.com

Leading Real Estate Agent in Queens, NY, Guides Buyers to Ideal Homes Amidst Competitive Market

In the fast-paced and ever-evolving real estate market of Queens, navigating the search for the perfect home can feel overwhelming. As a dedicated real estate agent in Queens, NY, Ahmed Drake is committed to providing personalized service that prioritizes clients’ unique needs and preferences. With his expertise, buyers can confidently explore their options and find a home that truly reflects their lifestyle.

Understanding the nuances of the local market is essential for buyers. Ahmed’s approach focuses on identifying properties that not only meet clients’ criteria but also offer great value. By utilizing data-driven insights and a thorough analysis of neighborhood trends, he empowers buyers to make informed decisions. Whether they are seeking a cozy apartment or a spacious family home, Ahmed will help them discover opportunities that align with their goals and dreams.

“My mission as a top Realtor agent in Queens, NY, is to ensure that every client finds a home they love,” says Ahmed Drake. “I take the time to listen to my clients’ needs and leverage my local market knowledge to guide them toward the best options available.”

Effective communication is at the heart of his service. He works closely with clients throughout the buying process, providing updates on new listings and market changes. His dedication extends beyond just closing the deal; he strives to ensure a seamless and enjoyable home-buying experience. As a leading Realtor in Queens, NY, Ahmed prioritizes transparency, keeping clients informed and engaged every step of the way. He aims to be the real estate selling agent in Queens, NY, who not only facilitates transactions but also builds lasting relationships.

For those looking to discover their ideal home in today’s competitive market, reaching out to Ahmed is the first step. Contact him today by phone or email, as well as visit the website at https://innovativesolutionsrealty.com. Together, you can navigate the complexities of real estate and turn homeownership dreams into reality. With Ahmed’s guidance, the home search can be a successful and rewarding journey!

Media Contact
Company Name: INNOVATIVE SOLUTIONS REALTY | Real Estate Agent in Queens, NY
Contact Person: Ahmed Drake
Email: Send Email
Phone: +1 929-335-7700
Address:176-27 137th Ave
City: Queens
State: New York 11434
Country: United States
Website: https://www.innovativesolutionsrealty.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Leading Real Estate Agent in Queens, NY, Guides Buyers to Ideal Homes Amidst Competitive Market

Kitchen Remodeling Contractor in Boca Raton, FL, Champions Functional Space Expansion

Boca Raton, FL – Expanding kitchen space while enhancing functionality is at the heart of contemporary home design trends. ABC Construction Building, a premier kitchen remodeling contractor in Boca Raton, FL, specializes in transforming cramped kitchens into spacious, multifunctional environments that cater to the needs of modern families.

Israel Morag, the owner of the company and the expert of oof construction and kitchen remodeling services in Boca Raton, FL emphasizes the importance of strategic planning in kitchen expansions. “It’s not just about making the kitchen bigger; it’s about making it smarter. Our goal is to optimize the layout to improve flow and usability, integrating state-of-the-art appliances and innovative storage solutions,” explains Morag. This approach ensures that every square inch of the new kitchen space is utilized effectively, enhancing both its aesthetic appeal and functional value.

The process often involves rethinking the existing structures within the home. “Many homeowners aren’t aware of the potential their kitchens have. Whether it’s removing a non-load-bearing wall to open up the area or reconfiguring the layout to incorporate an island or additional counterspace, our kitchen remodeling contractors in Boca Raton, FL, have the expertise to guide these decisions,” says Morag. These changes not only increase the kitchen’s footprint but also its role as a central gathering place in the home.

Additionally, ABC Construction focuses on integrating natural light and ventilation to create a more inviting space. “Incorporating elements like larger windows or a skylight can dramatically alter the feel of a kitchen, making it a brighter and more enjoyable space,” Morag notes. Such enhancements are a hallmark of the kitchen remodeling company in Boca Raton, FL, where the subtropical climate allows for an indoor-outdoor living style that many homeowners desire.

Homeowners looking to expand and modernize their kitchens can trust ABC Construction Building to deliver exceptional results. “Visit https://abcconstructionbuilding.com/ to see how we can transform your kitchen into a beautifully functional centerpiece of your home,” invites Morag. With a commitment to innovation and customer satisfaction, ABC Construction continues to be a leader in kitchen remodeling in Boca Raton, FL, turning ordinary kitchens into extraordinary culinary spaces.

Media Contact
Company Name: ABC Construction Building | Home builders in Delray Beach, FL
Contact Person: Israel Morag
Email: Send Email
Phone: +1 561-998-5776
Address:112 SE 10th St
City: Delray Beach
State: Florida 33444
Country: United States
Website: https://abcconstructionbuilding.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Kitchen Remodeling Contractor in Boca Raton, FL, Champions Functional Space Expansion

Introducing CORE, the Premier Portable Purifier that Effectively Filters All Types of Secondhand Smoke to Promote Healthier Environments

CORE will make its official debut December 4, 2024 with a crowdfunding campaign featuring exclusive perks for backers

CORE, the innovative, effective portable personal smoke purifier, will make its highly anticipated debut in December 4, 2024.

The makers of CORE considered the pain points of various kinds of smoke including negative health implications, foul odors, and pollution and set out on a mission to create a unique, one-of-a-kind device that would effectively eliminate smoke from the air. With CORE, this mission has been accomplished with the design of a handheld personal purifier that can be used by anyone, whether they smoke or not, to purify the air around them. Smoke is exhaled into CORE, and the handheld device filters out the smoke to keep air in the surrounding area clean. Nonsmokers can share this unique device with smokers so they can use CORE, too.

Statistics show that one smoker’s secondhand smoke can impact up to 30 people. CORE bridges the gap between smokers and nonsmokers, fostering better relationships between those who smoke and those who don’t with a simple groundbreaking device.

CORE is made with international standard and eco-friendly materials to ensure a premium quality product designed for longevity and environmental consciousness. Discreet yet practical and functional, CORE is the perfect on-the-go device for virtually anyone committed to cleaner air in shared spaces.

According to creators of CORE, their device is the most affordable and effective air purifying device available today. The first prototypes have received rave reviews from users, underscoring the effectiveness of this pioneering device that will give people everywhere the power to keep air free from smoke and its particulates. CORE will also debut with accessories such as STATION, a handheld dock allowing for one-handed use, and BREEZE, a specially formulated enzyme spray that purifies thirdhand smoke, which consists of harmful residues left on clothing, furniture, and other surfaces, and neutralizes combustion fumes.

CORE will debut on IndieGoGo on December 4, 2024. Between now and then, early birds can get exclusive discounts when they sign up at the CORE website. These discounts include up to 50% off CORE by just signing up to receive a private link upon the campaign’s launch. These discounts are limited in quantity and time, with no plans of offering them again in the future.  

When then campaign launches, backers will have the opportunity to pledge in exchange for perk packages including CORE, STATION, and more. Learn more and stay up to date at IndieGoGo at https://igg.me/at/corethepurifier.

ABOUT CORE

CORE is a portable smoke purification device that effectively filters out smoke, odors, and harmful particles to promote cleaner, healthier spaces. Say hello to the New Era of clean air. Follow CORE on social media: 

Facebook: @corethepurifier

Instagram: @core_the_purifier

TikTok: @core_the_purifier

Media Contact
Company Name: CORE
Contact Person: Adam Yu Nobuhiko
Email: Send Email
Country: United States
Website: https://www.thecoreproducts.com/